HopeStage
Back to all studies
RecruitingNCT07639359

Ketamine infusions for depressive symptoms in intensive care

About this titleRead the official source — NCT07639359

Researchers are comparing Ketamine (0.5 mg/kg) and placebo to find out how the approaches affect depression symptoms in people with depression.

Medication studyAges 18–99United States + Argentina
The study in practice

Understand this study

What is this study about?

Researchers are comparing Ketamine (0.5 mg/kg) and placebo to find out how the approaches affect depression symptoms in people with depression.

Who could participate?

Listed age limits: 18 years to 99 years.

What will I do during this study?

Participants are randomly assigned to intravenous ketamine or saline placebo (an inactive comparison treatment). The infusion is given once daily over 40 to 60 minutes for two consecutive days, with monitoring during treatment.

Listed locations
Jacksonville and 1 more locationSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 14, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
50
Sponsor
Hospital Italiano de Buenos Aires
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Argentina
Age range
From 18 Years to 99 Years
Official registry ID
NCT07639359
Official title
Show the full official title

Ketamine In Depression - Intensive Care Unit Trial (KID-ICU): A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Ketamine Infusion for Depressive Symptoms in Intensive Care Unit Patients

Recruitment & locations

Currently recruiting

Jacksonville, United States · Buenos Aires, Argentina

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Ketamine (0.5 mg/kg) and placebo to find out how the approaches affect depression symptoms in people with depression.

Who is behind this study?

The study sponsor is Hospital Italiano de Buenos Aires, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Ketamine (0.5 mg/kg).

Who can participate?

Listed age limits: 18 years to 99 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies